AnaptysBio Total Liabilities 2014-2025 | ANAB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AnaptysBio total liabilities from 2014 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

AnaptysBio total liabilities from 2014 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.6B
Amgen (AMGN)	$164.4B
Gilead Sciences (GILD)	$137B
Vertex Pharmaceuticals (VRTX)	$120.7B
Bristol Myers Squibb (BMY)	$97.7B
CSL (CSLLY)	$84.2B
GSK (GSK)	$75.8B
Regeneron Pharmaceuticals (REGN)	$60.6B
Alnylam Pharmaceuticals (ALNY)	$42.4B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$20.3B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$16.2B
Genmab (GMAB)	$14B
Genmab (GNMSF)	$13.8B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.1B
Exact Sciences (EXAS)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.8B